April 10, 2024
“April 9 (Reuters) – Israel’s data security firm Cyera has tripled its valuation to $1.4 billion in less than a year as it raised fresh capital in a series C funding led by U.S. tech-focused fund Coatue Management… The rapid… Continue Reading…
June 27, 2023
“Online money transfer firm Wise’s shares soared nearly 18% Tuesday as the company reported a spike in profits thanks to rising interest income. The company said in a statement to the stock market that its profit before tax tripled to £146.5 million… Continue Reading…
June 2, 2021
“Aeva Technologies (AEVA)… Rusch rates this stock as Outperform (i.e., a Buy), and his $20 price target implies it has room for 104% growth in the next 12 months… Wall Street generally is even more bullish here than Rusch is. The… Continue Reading…
May 27, 2021
“RedHill Biopharma (RDHL)… Overall, based on all the above factors, Wall Street analysts are thoroughly impressed with RDHL. It boasts 100% Street support, or 4 Buy ratings in the last three months, making the consensus a Strong Buy. Shares are selling… Continue Reading…
October 15, 2020
“Shares of Nio Inc. shot up 9.8% toward a record high in premarket trading Wednesday, after a bullish call on the China-based electric vehicle maker from J.P. Morgan. The stock was on track to open above the Oct. 12 record… Continue Reading…
October 13, 2020
“AutoWeb, Inc. (AUTO)… Overall, AutoWeb stands as a ‘Strong Buy’ name among Wall Street analysts. In the last three months, the stock has won 3 bullish recommendations. With a return potential of 81%, the stock’s consensus price target lands at $6.33…… Continue Reading…
September 19, 2020
“Bellicum Pharmaceuticals (BLCM)… Looking at the consensus breakdown, 2 Buys and no Holds or Sells have been published in the last three months. Therefore, BLCM gets a Moderate Buy consensus rating. Based on the $21.50 average price target, which is… Continue Reading…
September 2, 2020
“Baudax Bio (BXRX) First up we have Baudax Bio, which is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings. With shares changing hands for $2.80, Oppenheimer believes that the share price presents an attractive… Continue Reading…
Recent Comments